Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses

Yu,Chao‑Heng; Luo,Zi‑Chao; Li,Meng; Lu,Lian; Li,Zhan; Wu,Xiao‑Zhe; Fan,Ying‑Zi; Zhang,Hai‑Long; Zhou,Bai‑Ling; Wan,Yang; Men,Ke; Tian,Yao‑Mei; Chen,Shuang; Yuan,Feng‑Jiao; Xiang,Rong; Yang,Li

doi:10.3892/mmr.2015.4581

Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses

Authors:
- Chao‑Heng Yu
- Zi‑Chao Luo
- Meng Li
- Lian Lu
- Zhan Li
- Xiao‑Zhe Wu
- Ying‑Zi Fan
- Hai‑Long Zhang
- Bai‑Ling Zhou
- Yang Wan
- Ke Men
- Yao‑Mei Tian
- Shuang Chen
- Feng‑Jiao Yuan
- Rong Xiang
- Li Yang
View Affiliations

Affiliations: State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China, Department of Immunology, Nankai University School of Medicine, Nankai, Tianjin 300071, P.R. China
Published online on: November 19, 2015 https://doi.org/10.3892/mmr.2015.4581
Pages: 915-924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vaccines are critical tools for the prevention and treatment of several diseases. Adjuvants have been traditionally used to enhance immunity to vaccines and experimental antigens. In the present study, the adjuvant combination of CpG oligodeoxynucleotides (CpG ODN) and the innate defense regulator (IDR) peptide, IDR‑HH2, was evaluated for its ability to enhance and modulate the immune response when formulated with alum and the recombinant hepatitis B surface antigen (HBsAg). The CpG‑HH2 complex enhanced the secretions of tumor necrosis factor‑α, monocyte chemotactic protein 1 and interferon‑γ by human peripheral blood mononuclear cells and promoted murine bone marrow dentritic cell maturation. In addition, the present study demonstrated that IDR‑HH2 was chemotactic for human neutrophils, THP‑1 cells and RAW264.7 cells at concentrations between 2.5 and 40 µg/ml. The present study also observed that signiﬁcantly higher anti‑HBs antibody titers, which were sustained at high levels for as long as 35 weeks following the boost immunization, were induced by the combination adjuvant, even when co‑administered with a commercial hepatitis B vaccine at a low antigen dose (0.1 µg HBsAg). Notably, the level of IgG2a was almost equal to the level of IgG1, indicating that a balanced T helper (Th)1/Th2 immune response was elicited by the novel vaccine, which was consistent with the ELISpot results. These data suggest that the CpG‑HH2 complex may be a potential effective adjuvant, which facilitates a reduction in the dose of antigen and induces long‑lasting, balanced immune responses.

View Figures

View References

1	Reed SG, Orr MT and Fox CB: Key roles of adjuvants in modern vaccines. Nat Med. 19:1597–1608. 2013. View Article : Google Scholar : PubMed/NCBI
2	Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, Babiuk LA and Potter A: Combination adjuvants: The next generation of adjuvants? Expert Rev Vaccines. 10:95–107. 2011. View Article : Google Scholar
3	Aebig JA, Mullen GE, Dobrescu G, Rausch K, Lambert L, Ajose-Popoola O, Long CA, Saul A and Miles AP: Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods. 323:139–146. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kovacs-Nolan J, Latimer L, Landi A, Jenssen H, Hancock RE, Babiuk LA and van Drunen Littel-van den Hurk S: The novel adjuvant combination of CpG ODN, indolicidin and polyphos-phazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine. 27:2055–2064. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cao D, Li H, Jiang Z, Xu C, Cheng Q, Yang Z, Cao G and Zhang L: Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets. Vaccine. 28:6006–6013. 2010. View Article : Google Scholar : PubMed/NCBI
6	Weeratna RD, Brazolot Millan CL, McCluskie MJ and Davis HL: CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol. 32:65–71. 2001. View Article : Google Scholar : PubMed/NCBI
7	Thaker HD, Som A, Ayaz F, Lui D, Pan W, Scott RW, Anguita J and Tew GN: Synthetic mimics of antimicrobial peptides with immunomodulatory responses. J Am Chem Soc. 134:11088–11091. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hancock RE and Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 24:1551–1557. 2006. View Article : Google Scholar : PubMed/NCBI
9	Li M, Shi H, Mu Y, Luo Z, Zhang H, Wan Y, Zhang D, Lu L, Men K, Tian Y, et al: Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer. 13:1792014. View Article : Google Scholar : PubMed/NCBI
10	Wu X, Wang Z, Li X, Fan Y, He G, Wan Y, Yu C, Tang J, Li M, Zhang X, et al: In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method. Antimicrob Agents Chemother. 58:5342–5349. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kindrachuk J, Jenssen H, Elliott M, Townsend R, Nijnik A, Lee SF, Gerdts V, Babiuk LA, Halperin SA and Hancock RE: A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine. 27:4662–4671. 2009. View Article : Google Scholar : PubMed/NCBI
12	Niyonsaba F, Madera L, Afacan N, Okumura K, Ogawa H and Hancock RE: The innate defense regulator peptides IDR-HH2, IDR-1002 and IDR-1018 modulate human neutrophil functions. J Leukoc Biol. 94:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
13	Klinman DM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2:305–315. 2003. View Article : Google Scholar : PubMed/NCBI
14	Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, et al: Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasma-cytoid dendritic cells. Cancer Res. 71:6428–6437. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW and Heathcote J: CPG 7909, an immu-nostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. J Clin Immunol. 24:693–701. 2004. View Article : Google Scholar : PubMed/NCBI
16	Lee CC, Avalos AM and Ploegh HL: Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol. 12:168–179. 2012.PubMed/NCBI
17	Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, Seder RA and Sacks DL: Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun. 71:5121–5129. 2003. View Article : Google Scholar : PubMed/NCBI
18	Brown TH, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, Hancock RE, Xing Z, Halperin SA and Wang J: Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. Vaccine. 30:350–360. 2012. View Article : Google Scholar
19	Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC and Hoffman SL: CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun. 72:949–957. 2004. View Article : Google Scholar : PubMed/NCBI
20	Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT and Tao MH: Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol. 160:1320–1329. 1998.PubMed/NCBI
21	Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, et al: An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 25:465–472. 2007. View Article : Google Scholar : PubMed/NCBI
22	Ishida T, Oyama T, Carbone DP and Gabrilovich DI: Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol. 161:4842–4851. 1998.PubMed/NCBI
23	Mackay CR: Chemokines: Immunology's high impact factors. Nat Immunol. 2:95–101. 2001. View Article : Google Scholar : PubMed/NCBI
24	Billeskov R, Elvang TT, Andersen PL and Dietrich J: The HyVac4 subunit vaccine efficiently boosts BCG- primed anti- mycobac-terial protective immunity. PLoS One. 7:e399092012. View Article : Google Scholar
25	Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P and Chisari FV: Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 228:1195–1199. 1985. View Article : Google Scholar : PubMed/NCBI
26	Liljeqvist S and Stahl S: Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol. 73:1–33. 1999. View Article : Google Scholar : PubMed/NCBI
27	Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, et al: Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 17:479–487. 2011. View Article : Google Scholar : PubMed/NCBI
28	Fritz JH, Brunner S, Birnstiel ML, Buschle M, Gabain Av, Mattner F and Zauner W: The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine. 22:3274–3284. 2004. View Article : Google Scholar : PubMed/NCBI
29	Huang W, Seo J, Willingham SB, Czyzewski AM, Gonzalgo ML, Weissman IL and Barron AE: Learning from host-defense peptides: Cationic, amphipathic peptoids with potent anticancer activity. PLoS One. 9:e903972014. View Article : Google Scholar : PubMed/NCBI
30	Ren SX, Cheng AS, To KF, Tong JH, Li MS, Shen J, Wong CC, Zhang L, Chan RL, Wang XJ, et al: Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 72:6512–6523. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hurtado P and Peh CA: LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol. 184:1425–1435. 2010. View Article : Google Scholar : PubMed/NCBI
32	Soehnlein O, Kai-Larsen Y, Frithiof R, Sorensen OE, Kenne E, Scharffetter-Kochanek K, Eriksson EE, Herwald H, Agerberth B and Lindbom L: Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest. 118:3491–3502. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hilchie AL, Wuerth K and Hancock RE: Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol. 9:761–768. 2013. View Article : Google Scholar : PubMed/NCBI
34	Harder J, Bartels J, Christophers E and Schröder JM: A peptide antibiotic from human skin. Nature. 387:8611997. View Article : Google Scholar : PubMed/NCBI
35	Bode C, Zhao G, Steinhagen F, Kinjo T and Klinman DM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 10:499–511. 2011. View Article : Google Scholar : PubMed/NCBI
36	Klinman DM, Yi AK, Beaucage SL, Conover J and Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma. Proc Natl Acad Sci USA. 93:2879–2883. 1996. View Article : Google Scholar
37	Klinman DM: Immunotherapeutic uses of CpG oligodeoxy-nucleotides. Nat Rev Immunol. 4:249–258. 2004. View Article : Google Scholar : PubMed/NCBI
38	Weeratna RD, McCluskie MJ, Xu Y and Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:1755–1762. 2000. View Article : Google Scholar : PubMed/NCBI
39	Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA and Davis HL: CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 95:15553–15558. 1998. View Article : Google Scholar : PubMed/NCBI
40	Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA and Yunis EJ: Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol. 58:42–51. 1997. View Article : Google Scholar
41	Larsen CE, Xu J, Lee S, Dubey DP, Uko G, Yunis EJ and Alper CA: Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine. 18:3021–3030. 2000. View Article : Google Scholar : PubMed/NCBI
42	Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, Soyano A, Diaz Y and Berrueta L: The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology. 326:20–28. 2004. View Article : Google Scholar : PubMed/NCBI
43	Chiou SS, Yamauchi K, Nakanishi T and Obata H: Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology. 64:545–550. 1988.PubMed/NCBI
44	Shokrgozar MA and Shokri F: Enumeration of hepatitis B surface antigen- specific B lymphocytes in responder and non- responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology. 104:75–79. 2001. View Article : Google Scholar : PubMed/NCBI